Sandoz Prepares For European Natalizumab Launch As Approval Arrives
Company Offers Indications Of Launch Timing For Tyruko Biosimilar Rival To Tysabri
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
